| Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021 | 1610 | 2021 |
| Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial PM Voorhees, JL Kaufman, J Laubach, DW Sborov, B Reeves, ... Blood, The Journal of the American Society of Hematology 136 (8), 936-945, 2020 | 637 | 2020 |
| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 262 | 2022 |
| Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. NC Munshi, LD Anderson, Jr, N Shah, S Jagannath, JG Berdeja, S Lonial, ... Journal of Clinical Oncology 38 (15_suppl), 8503-8503, 2020 | 129 | 2020 |
| Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease LD Anderson Jr, CA Savary, CA Mullen Blood, The Journal of the American Society of Hematology 95 (7), 2426-2433, 2000 | 91 | 2000 |
| KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma S Jagannath, Y Lin, H Goldschmidt, D Reece, A Nooka, A Senin, ... Blood cancer journal 11 (6), 116, 2021 | 68 | 2021 |
| Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated … LD Anderson, N Shah, S Jagannath, JG Berdeja, S Lonial, N Raje, ... 18th International Myeloma Workshop, 8-11, 2021 | 58 | 2021 |
| Results from Lummicar-2: a phase 1b/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and/or refractory multiple myeloma SK Kumar, RC Baz, RZ Orlowski, LD Anderson Jr, H Ma, A Shrewsbury, ... Blood 136, 28-29, 2020 | 58 | 2020 |
| Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse M Dimopoulos, K Weisel, P Moreau, LD Anderson, D White, J San-Miguel, ... Leukemia 35 (6), 1722-1731, 2021 | 49 | 2021 |
| Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of … JL Kaufman, JP Laubach, D Sborov, B Reeves, C Rodriguez, A Chari, ... Blood 136, 45-46, 2020 | 46 | 2020 |
| Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease LD Anderson Jr, S Mori, S Mann, CA Savary, CA Mullen Cancer research 60 (20), 5797-5802, 2000 | 46 | 2000 |
| Enhancement of Graft-Versus-Tumor Activity and Graft-Versus-Host Disease by Pretransplant Immunization of Allogeneic Bone Marrow Donors with a Recipient … LD Anderson Jr, D Petropoulos, LA Everse, CA Mullen Cancer research 59 (7), 1525-1530, 1999 | 43 | 1999 |
| Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results PG Richardson, WI Bensinger, CA Huff, CL Costello, N Lendvai, ... British journal of haematology 180 (6), 821-830, 2018 | 40 | 2018 |
| Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis … JP Laubach, JL Kaufman, DW Sborov, B Reeves, C Rodriguez, A Chari, ... Blood 138, 79, 2021 | 39 | 2021 |
| First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-cell maturation antigen (BCMA) in patients with relapsed … AD Cohen, R Popat, S Trudel, PG Richardson, EN Libby III, N Lendvai, ... Blood 128 (22), 1148, 2016 | 39 | 2016 |
| Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma LD Anderson Jr Future Oncology 18 (3), 277-289, 2022 | 36 | 2022 |
| Stem cell mobilization yields with daratumumab-and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and … S Chhabra, N Callander, NL Watts, LJ Costa, B Thapa, JL Kaufman, ... Transplantation and Cellular Therapy 29 (3), 174. e1-174. e10, 2023 | 35 | 2023 |
| A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease D Lambracht-Washington, B Qu, M Fu, LD Anderson Jr, TN Eagar, ... Journal of neuroimmunology 254 (1-2), 63-68, 2013 | 35 | 2013 |
| Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood cancer journal 13 (1), 117, 2023 | 34 | 2023 |
| Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma A Chari, S Larson, B Holkova, RF Cornell, C Gasparetto, C Karanes, ... Leukemia & lymphoma 59 (11), 2588-2594, 2018 | 26 | 2018 |
